Onconetix (ONCO) Non Operating Income (2023 - 2026)
Onconetix (ONCO) posted quarterly Non Operating Income of $6.0 million for Q1 2026, up 49.34% year-over-year from $4.0 million in Q1 2025, and down 13.53% quarter-over-quarter from $7.0 million in Q4 2025.
Onconetix (ONCO) Non Operating Income (2023 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Non Operating Income for 4 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 49.34% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $5.8 million (up 521.07% YoY), while the FY2025 annual figure was $3.8 million, up 217.79% from the prior year.
- Non Operating Income declined to $6.0 million in Q1 2026 per ONCO's latest filing, from $7.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $7.0 million in Q4 2025 and bottomed at -$6.7 million in Q3 2025.
- Historically, Non Operating Income has averaged $433267.4 across 4 years, with a median of -$375918.0 in 2023.
- On a YoY basis, Non Operating Income climbed as much as 2645.03% in 2025 and fell as far as 442.4% in 2025.
- Onconetix's Non Operating Income stood at -$314812.0 in 2023, then sank by 284.5% to -$1.2 million in 2024, then soared by 674.29% to $7.0 million in 2025, then dropped by 13.53% to $6.0 million in 2026.
- Business Quant data shows ONCO's Non Operating Income at $6.0 million in Q1 2026, $7.0 million in Q4 2025, and -$6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -136,513.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -136,513.00 |
| Mar 31, 2026 | 6.01 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Sep 30, 2025 | -6.71 Mn |
| Jun 30, 2025 | -437,024.00 |
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | -1.21 Mn |
| Sep 30, 2024 | -1.24 Mn |
| Jun 30, 2024 | -640,917.00 |
| Mar 31, 2024 | -158,149.00 |
| Dec 31, 2023 | -314,812.00 |
| Sep 30, 2023 | -858,825.00 |
| Jun 30, 2023 | -215,670.00 |